Logistic regression analysis with sex, age, arthritis and alanine aminotransferase levels at tocilizumab initiation as covariates revealed the presence of arthritis at tocilizumab initiation as a significant negative factor for remission achievement at 6 months with tocilizumab (odds ratio, 0.08 [95% CI 0.01–0.80], P = 0.03, Supplementary Table S2, available at Rheumatology online). This evidence concerns the gene GPT and arthritic joint disease.